The results of alcohol septal ablation in patients with hypertrophic cardiomiopathy and arterial hypertension
DOI:
https://doi.org/10.14739/2310-1210.2020.1.194463Keywords:
hypertrophic cardiomyopathy, hypertension, catheter ablationAbstract
Objective: to study the impact of arterial hypertension on the results of treatment in patients with hypertrophic cardiomyopathy (HCM) with alcohol septal ablation (ASA) in short-term and long-term follow-up.
Materials and methods. The study included 115 patients with HCM who underwent primary isolated ASA during 2009–2018 years at Amosov National Institute of Cardiovascular Surgery of the NAMS of Ukraine and were divided into 2 groups: 44 (38.3 %) with accompanying arterial hypertension (AH) and 71 (61.7 %) without it.
Results. Statistically significant decreases in the systolic pressure gradient, mitral regurgitation, NYHA functional class in both groups within short- and long-term periods were proved. There was a statistically significant increase in complete right-bundle branch blocks in both groups, whereas the quantity of implanted pacemakers due to complete AV-block in patients after ASA did not increase statistically. Among the patients with AH, 31 patients (70.4 %) had good result, 3 (6.8 %) – relatively unsatisfactory, 10 (22.7 %) – unsatisfactory in the short-term period. Among the patients without AH, the good result had 42 patients (59.1 %), relatively unsatisfactory – 3 (4.2 %), unsatisfactory – 26 (36.6 %). In the long-term period, among the patients with AH, 32 (80.0 %) had good hemodynamic result, 1 (2.5 %) – relatively unsatisfactory, 7 (17.5 %) – unsatisfactory; among the patients without AH – 43 (64.2 %), 4 (6.0 %) and 20 (29.8 %) patients, respectively. There was no statistically significant difference in results between two groups neither in short-term, nor in the long-term period.
Conclusions. The results of the study showed that comorbid arterial hypertension in patient with obstructive hypertrophic cardiomyopathy who underwent ASA does not affect the short- and long-term parameters of the systolic pressure gradient in left ventricular outflow tract, mitral insufficiency, interventricular septum thickness, NYHA functional class, rate of non-fatal outcomes (complete right-bundle branch block, complete AV-block), mortality.
References
Argulian, E., Messerli, F. H., Aziz, E. F., Winson, G., Agarwal, V., Kaddaha, F., Kim, B., & Sherrid, M. V. (2013). Antihypertensive Therapy in Hypertrophic Cardiomyopathy. The American Journal of Cardiology, 111(7), 1040–1045. https://doi.org/10.1016/j.amjcard.2012.12.026
Gil, T., Castier, M., Gondar, A., Sales, A., Santos, M., Lima, F., & Mourilhe-Rocha, R. (2019). Strain Analysis of Left Ventricular Function in the Association of Hypertrophic Cardiomyopathy and Systemic Arterial Hypertension. Arquivos Brasileiros De Cardiologia, 113(4), 677 684. https://doi.org/10.5935/abc.20190176
Morita, H., Larson, M. G., Barr, S. C., Vasan, R. S., O’Donnell, C. J., Hirschhorn, J. N., Levy, D., Corey, D., Seidman, C. E., Seidman, J. G., & Benjamin, E. J. (2006). Single-Gene Mutations and Increased Left Ventricular Wall Thickness in the Community. Circulation, 113(23), 2697–2705. https://doi.org/10.1161/circulationaha.105.593558
Veselka, J., Jensen, M. K., Liebregts, M., Januska, J., Krejci, J., Bartel, T., Dabrowski, M., Hansen, P. R., Almaas, V. M., Seggewiss, H., Horstkotte, D., Tomasov, P., Adlova, R., Bundgaard, H., Steggerda, R., ten Berg, J., & Faber, L. (2016). Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. European Heart Journal, 37(19), 1517–1523. https://doi.org/10.1093/eurheartj/ehv693
Li, C.-Y., & Shi, Y.-Q. (2019). Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy. Arquivos Brasileiros de Cardiologia, 112(4), 432–438. https://doi.org/10.5935/abc.20190060
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., Mahrholdt, H., McKenna, W. J., Mogensen, J., Nihoyannopoulos, P., Nistri, S., Pieper, P. G., Pieske, B., Rapezzi, C., Rutten, F. H., Tillmanns, C., ... Sekhri, N. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 35(39), 2733 2779. https://doi.org/10.1093/eurheartj/ehu284
Spaziano, M., & Lefèvre, T. (2016). L’alcoolisation septale dans la cardiomyopathie hypertrophique obstructive: indications, aspects techniques et résultats cliniques [Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: indications, technical aspects and clinical results]. Sang Thrombose Vaisseaux, 28(6), 251–261. https://doi.org/10.1684/stv.2016.0959
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)